Managing ARPI Toxicities and Treatment Goals in mCSPC

This episode, titled ‘Managing ARPI Toxicities and Treatment Goals in mCSPC,’ features panelists discussing how treatment-related toxicities and individual patient factors influence therapeutic decision-making in metastatic castration-sensitive prostate cancer (mCSPC). The expert faculty emphasize that while ARPI-based therapies have significantly improved outcomes, successful treatment requires balancing clinical benefit with quality of life and long-term tolerability.

Throughout the discussion, the panel explores how comorbidities, particularly cardiovascular risk, can shape treatment selection and monitoring strategies. They highlight the importance of multidisciplinary care, proactive toxicity management, and ongoing communication with patients to help maintain adherence and address adverse effects before they become barriers to treatment. The panelists also discuss the role of patient education in setting expectations and supporting shared decision-making throughout the treatment journey.

The conversation further examines how patient priorities influence therapy selection and how clinicians navigate discussions around treatment goals, efficacy data, and clinical trial outcomes. Rather than focusing solely on study endpoints, the expert faculty stress the importance of understanding each patient’s overall health status, preferences, and treatment expectations. Ultimately, they emphasize that individualized care, thoughtful toxicity management, and collaboration between patients and providers remain essential to optimizing outcomes for patients with mCSPC.

In the next episode, ‘Navigating Access and Treatment Discussions in mCSPC,’ the panelists discuss how access barriers and real-world treatment considerations influence ARPI selection in mCSPC. They explore how clinicians communicate treatment options, address practical challenges, and individualize therapy based on each patient's needs and circumstances.